<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05627271</url>
  </required_header>
  <id_info>
    <org_study_id>COMB157G2012</org_study_id>
    <nct_id>NCT05627271</nct_id>
  </id_info>
  <brief_title>The 'Wearing Off' Effect of DMT</brief_title>
  <official_title>Understanding the 'Wearing Off' Effect From Disease-modifying Therapies (DMT) in Patients With Multiple Sclerosis: an Interview Based Study Among Patients and Clinicians</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a non-interventional, cross-sectional, qualitative study in which patients diagnosed&#xD;
      with MS and clinicians with experience treating MS will be interviewed regarding patient&#xD;
      experiences with the wearing off effect from ocrelizumab, natalizumab, and ofatumumab&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2023</start_date>
  <completion_date type="Anticipated">May 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 5, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with key symptoms associated with the wearing off effect</measure>
    <time_frame>Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months</time_frame>
    <description>Number of participants with the following recurring symptoms will be collected:&#xD;
Fatigue&#xD;
Physical Pain&#xD;
Mobility issues or walking difficulties&#xD;
Numbness or sensory issues&#xD;
Cognitive difficulties&#xD;
Weakness&#xD;
Spasms&#xD;
Balance disturbance or dizziness&#xD;
Blurry vision or visual impairment&#xD;
Others</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of wearing off effect symptoms</measure>
    <time_frame>Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months</time_frame>
    <description>Based on qualitative score rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detailed language used to describe the experience of wearing off effect</measure>
    <time_frame>Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months</time_frame>
    <description>Terms used to describe times when patients MS &quot;gets better&quot; and when it &quot;gets worse&quot; will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants switching from one therapy to another due to wearing off effect</measure>
    <time_frame>Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months</time_frame>
    <description>Number of participants switching from one therapy to another due to wearing off effect will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who changed the dosing/infusion schedules due to wearing off effect</measure>
    <time_frame>Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months</time_frame>
    <description>Number of participants who changed the dosing/infusion schedules due to wearing off effect will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dissimilarities of clinician' and patients' views of wearing off effect</measure>
    <time_frame>Assessed at the time of interview with lookback period from time of first MS diagnosis, up to 3 months</time_frame>
    <description>Assessed qualitatively via concept coding techniques</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>ocrelizumab</arm_group_label>
    <description>patients prescribed with ocrelizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>natalizumab</arm_group_label>
    <description>Patients prescribed with natalizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ofatumumab</arm_group_label>
    <description>Patients prescribed with ofatumumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ocrelizumab</intervention_name>
    <description>Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.</description>
    <arm_group_label>ocrelizumab</arm_group_label>
    <other_name>Ocrevus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>natalizumab</intervention_name>
    <description>Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.</description>
    <arm_group_label>natalizumab</arm_group_label>
    <other_name>Tysabri</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ofatumumab</intervention_name>
    <description>Non-interventional, cross-sectional, qualitative study. There is no treatment allocation. Patients prescribed with Disease-modifying therapy in the commercial setting are eligible to enroll into this study.</description>
    <arm_group_label>ofatumumab</arm_group_label>
    <other_name>Kesimpta</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients diagnosed with MS and clinicians with experience treating MS from Germany,&#xD;
        UK, and US&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who attend the following criteria will be included:&#xD;
&#xD;
          1. Age ≥18;&#xD;
&#xD;
          2. Current resident of the country of interest (i.e., Germany, the UK, or the US);&#xD;
&#xD;
          3. Relapsing-remitting MS diagnosis confirmed by a clinician;&#xD;
&#xD;
          4. Currently taking at least one of the following DMTs for MS after the maintenance&#xD;
             phase: ocrelizumab (Ocrevus®), natalizumab (Tysabri®), or ofatumumab (Kesimpta®);&#xD;
&#xD;
          5. Two or more consecutive ocrelizumab doses (Six or more consecutive natalizumab doses&#xD;
             or Six or more consecutive ofatumumab doses);&#xD;
&#xD;
          6. Follow the approved dosing regimen (Ocrelizumab: every six months or Natalizumab:&#xD;
             every month or Ofatumumab: every month);&#xD;
&#xD;
          7. Experienced reoccurring symptoms towards the end of the dosing cycle (i.e., the&#xD;
             wearing off effect);&#xD;
&#xD;
          8. Willing and able to provide informed consent via a weblink, indicating they understand&#xD;
             the study purpose and procedures and are willing to participate;&#xD;
&#xD;
          9. Able to read, understand, and communicate in English or German;&#xD;
&#xD;
         10. Willing and able to participate in a phone/web-based (remote) one-on-one interview,&#xD;
             and to be audio-recorded;&#xD;
&#xD;
         11. Have an e-mail address and will have access to a computer or smartphone at the time of&#xD;
             the interview to complete the electronic consent form.&#xD;
&#xD;
        Clinicians who attend the following criteria will be included:&#xD;
&#xD;
          1. Currently practices in one of the target countries (i.e., Germany, the UK, or the US);&#xD;
&#xD;
          2. Is a licensed clinician with a specialty in neurology;&#xD;
&#xD;
          3. Has prescribed at least one of the following DMTs within the last year: ocrelizumab&#xD;
             (Ocrevus®), natalizumab (Tysabri®), or ofatumumab (Kesimpta®);&#xD;
&#xD;
          4. Has treated at least 16 MS patients within the last month;&#xD;
&#xD;
          5. Is personally responsible for treatment decisions for their patients;&#xD;
&#xD;
          6. Has followed patients treating MS with any of the three DMTs for a. Two or more&#xD;
             consecutive ocrelizumab doses or b. Six or more consecutive natalizumab doses. c. Six&#xD;
             or more consecutive ofatumumab doses;&#xD;
&#xD;
          7. Has treated patients who have experienced specific reoccurring symptoms towards the&#xD;
             end of the dosing cycle (i.e., the wearing off effect);&#xD;
&#xD;
          8. Willing and able to provide informed consent via a weblink, indicating they understand&#xD;
             the study purpose and procedures and are willing to participate;&#xD;
&#xD;
          9. Willing and able to participate in a phone/web-based interview, and to be&#xD;
             audio-recorded.&#xD;
&#xD;
         10. Able to read, understand, and communicate in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded from the enrollment if:&#xD;
&#xD;
          1. Has a diagnosis of clinically isolated MS syndrome, primary progressive MS, or&#xD;
             secondary progressive MS;&#xD;
&#xD;
          2. Currently participates in an interventional MS clinical trial.&#xD;
&#xD;
        Clinicians will be excluded from the enrollment if are currently involved as a key opinion&#xD;
        leader or receives funding from one of the drug manufacturers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>November 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2022</study_first_posted>
  <last_update_submitted>May 2, 2023</last_update_submitted>
  <last_update_submitted_qc>May 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>ocrelizumab</keyword>
  <keyword>Ocrevus</keyword>
  <keyword>natalizumab</keyword>
  <keyword>Tysabri</keyword>
  <keyword>ofatumumab</keyword>
  <keyword>Kesimpta</keyword>
  <keyword>NIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Ocrelizumab</mesh_term>
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

